Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Cancer Res. 2021 Nov 4;82(1):169–176. doi: 10.1158/0008-5472.CAN-21-1467

Fig. 1. Transcriptomic and genomic characterization of HGSOC response to neoadjuvant chemotherapy.

Fig. 1.

(A) Overview of cohort and sample collection time points. Representative H&E of matched pairs of pre- and post-NACT samples from tumors with poor pathologic response to therapy (CRS 1) or excellent response to therapy (CRS 3; 40× magnification). (B) RNA-sequencing of whole transcriptome showed that samples cluster based on treatment status (pre- or post-NACT) rather than chemo-sensitivity, as visualized with t-SNE. CRS = chemotherapy response score; NACT = neoadjuvant chemotherapy; t-SNE = t-distributed stochastic neighbor embedding. (C) Molecular subtype2 of indicated patients before and after NACT. Patient molecular subtypes are plastic and frequently change after NACT.